Joyce O'Shaughnessy, MD
Enriched profileCo-chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research, Baylor University Charles A. Sammons Cancer Center · Baylor University Charles A. Sammons Cancer Center
Joyce O'Shaughnessy is Co-chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research, Baylor University Charles A. Sammons Cancer Center at Baylor University Charles A. Sammons Cancer Center. OpenAlex indexes 1,346 publications with 55,533 citations (h-index 100); ClinicalTrials.gov lists 13 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory.
Data verified 18 Oct 2026
Overview
Updated 18 Oct 2026
Joyce O'Shaughnessy, MD, is Co-chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research, Baylor University Charles A. Sammons Cancer Center. The public record shows 1,346 publications with 55,533 citations (h-index 100), centered on Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 46 companies.
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Breast Cancer Treatment Studies
- 13 registered trials on ClinicalTrials.gov
- Open Payments reporting from 46 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 9 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 404.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- Breast Cancer Index (BCI) Registry
Sponsor: Biotheranostics, Inc.
- Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
Sponsor: Baylor Research Institute
Industry payments
Updated 18 Oct 2026
46 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202514 payments$28,991openpaymentsdata.cms.gov ↗
- Eli Lilly and CompanyProgram year202525 payments$22,328openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20256 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
65.5%PD-1 inhibitor26%Pembrolizumab74%Nivolumab26%Part B, office-administered≥54 patientsMicrotubule Inhibitor11.2%Paclitaxel83%Docetaxel17%Part B, office-administered≥40 patients+ 13 more classes in this area
Metabolism & gastrointestinal
20.2%Other antiemetics17.6%Fosaprepitant100%Part B, office-administered≥83 patientsSerotonin-3 Receptor Antagonist2.4%Palonosetron hcl66%Granisetron hydrochloride33%Ondansetron Odt1%Part D + Part B≥104 patients+ 3 more classes in this area
Musculoskeletal
3.3%RANK Ligand Inhibitor3.1%Denosumab100%Part B, office-administered≥24 patientsBisphosphonate0.2%Zoledronic acid100%Part B, office-administered≥47 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 18 Oct 2026
447 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer.
Cancer medicine
Clinical Trial2026 - A clinical systematic literature review of treatments among patients with advanced and/or metastatic human epidermal growth factor receptor 2 positive breast cancer.
Journal of comparative effectiveness research
Review2024
Most-cited works
by citation count (OpenAlex)- 01Pembrolizumab for Early Triple-Negative Breast CancerArticle3,240 citations2020
- 02
- 03Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast CancerArticle2,022 citations2016
- 04Sacituzumab Govitecan in Metastatic Triple-Negative Breast CancerArticle1,690 citations2021
- 05Event-free Survival with Pembrolizumab in Early Triple-Negative Breast CancerArticle1,258 citations2022
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Yale University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗
- Undergraduate degree
Holy Cross College
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- Associate Editor
Clinical Breast Cancer Journal
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗ - Scientific Advisory Board
US Oncology Research Network
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →breastcancer.org ↗ - Chair
AACR Task Force on Treatment of Intraepithelial Neoplasia
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →giantsofcancercare.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →giantsofcancercare.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
Secondary affiliations
appointments beyond the home institution- Chair of the Breast Disease Committee
Sarah Cannon Research Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nbcdfw.com ↗ - Chair
US Oncology Network Breast Cancer Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Founder and Director
School of Breast Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nbcdfw.com ↗ - Founder
International Congress on the Future of Breast Cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →giantsofcancercare.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →wfaa.com ↗
- VUmedi video: Communicating the Risk of Recurrence for Patients with HR-
HER2- Early Breast Cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vumedi.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Norman Wolmark, MD
University of Pittsburgh
Hope Rugo, MD
City of Hope